5-(2,2-二甲基-1,3-二氧戊环-4-基)-2,2-二甲基四氢呋喃并[2,3-d][1,3]二氧杂环戊烯 | 2774-29-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-(2,2-二甲基-1,3-二氧戊环-4-基)-2,2-二甲基四氢呋喃并[2,3-d][1,3]二氧杂环戊烯
• 中文别名: 蔗糖脂
• 英文名称: (3aR,5R,6aR)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole
• 英文别名: 1,2:5,6-di-O-isopropylidene-3-deoxy-α-D-gulo-1,4-furanose；3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-xylo-hexofuranose；3-deoxy-galactofuranose；O¹,O²;O⁵,O⁶-diisopropylidene-α-D-xylo-3-deoxy-hexofuranose；O¹,O²;O⁵,O⁶-Diisopropyliden-α-D-xylo-3-desoxy-hexofuranose；(3AR,5R,6AR)-5-((R)-2,2-Dimethyl-1,3-dioxolan-4-YL)-2,2-dimethyltetrahydrofuro[2,3-D][1,3]dioxole；(3aR,5R,6aR)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxole
• CAS: 2774-29-0
• 化学式: C₁₂H₂₀O₅
• 分子量: 244.288
• InChiKey: AKKRBVFGAWFTRW-ZYUZMQFOSA-N

物化性质

• 熔点：
  78-80 °C
• 沸点：
  291.0±40.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、乙酸乙酯

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(2,2-二甲基-1,3-二氧戊环-4-基)-2,2-二甲基四氢呋喃并[2,3-d][1,3]二氧杂环戊烯 在 溶剂黄146 作用下， 反应 5.0h， 以70%的产率得到3-deoxy-1,2-O-isopropylidene-D-glucose
  参考文献：
  名称：

  一种抗病毒药物恩替卡韦的制备方法

  摘要：

  本发明涉及一种抗病毒药物恩替卡韦的制备方法，该方法以D-葡萄糖与丙酮为起始原料，具有易于操作、收率高、分离纯化容易的特点，其原料来源较广，成本较低，从反应一开始就控制了反应的选择性和立体性，能有效抑制手性异构体的产生，产物纯化方法简单且收率较高，关键中间体4-羟甲基-5-亚甲基环戊烷-1，3-二醇，并对其4-羟甲基用三苯基氯甲烷进行选择性保护，经mitsunobu与6氯鸟嘌呤结合，由于空间位阻效应，该保护基不仅能有效保护目标基团，而且在脱除保护基时也易于操作进行。

  公开号：

  CN102417506B
• 作为产物：
  描述：

  1,2:5,6-di-O-isopropylidene-3-O-tosyl-α-D-glucofuranoside 在 二氧化碳 、 氢气 、 钯 、 potassium hydroxide 作用下， 以 乙酸乙酯 、 甲苯 为溶剂， 反应 5.0h， 生成 5-(2,2-二甲基-1,3-二氧戊环-4-基)-2,2-二甲基四氢呋喃并[2,3-d][1,3]二氧杂环戊烯
  参考文献：
  名称：

  [EN] NOVEL SUGAR DERIVATIVES AND USES THEREOF TO PREPARE NOVEL SENOLYTIC AGENTS
  [FR] NOUVEAUX DÉRIVÉS DE SUCRE ET LEURS UTILISATIONS POUR PRÉPARER DE NOUVEAUX AGENTS SÉNOLYTIQUES

  摘要：

  Provided herein are novel sugar derivatives which are intermediates for preparing senolytic agents that selectively kill senescent cells associated with numerous pathologies and diseases, including age-related pathologies and diseases.

  公开号：

  WO2023039292A2

文献信息

• [EN] NOVEL GALACTOSIDE INHIBITOR OF GALECTINS<br/>[FR] NOUVEL INHIBITEUR DE GALECTINES DU TYPE GALACTOSIDE
  申请人：GALECTO BIOTECH AB

  公开号：WO2021001538A1

  公开（公告）日：2021-01-07

  The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors for use in treatment of inflammation; Inflammation induced thrombosis; Atopic dermatitis; Acute coronary syndrome; fibrosis, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, ophthalmological fibrosis and fibrosis of the skin and heart; local fibrosis such as Dupuytren's disease and Peyronie's disease; fibrotic complications of other therapies such as coronary stents, bile duct stents, cerebral artery stents, ureter stents; scleroderma; scarring; keloid formation; covid-19; acute lung injury; ARDS; viral pneumonitis, aberrant scar formation; surgical adhesions; septic shock; cancer, such as colorectal cancer, other gastrointestinal carcinomas such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancers, mesothelioma, female cancers like breast cancer, ovarian cancer, uterine cancer, cancer of the cervix uteri, cancer of the salpingx, cerebral cancers such as medulloblastomao, glioma, meningioma, sarcomas of the bones and muscles and other sarcomas, leukemias and lymphomas, such as T-cell lymphomas; transplant rejection; metastasising cancers; ageing; Dementia; Alzheimers; TGFbeta driven bone disease such as osteogenesis imperfecta; Pulmonary hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, Rheumatoid lung; Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, Herpes virus, Coronaviruses, Hepatitis C; metabolic disorders; heart disease; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, e.g. neovascularization related to cancer; and eye diseases, such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistens; obesity; Marfans syndrome; Loeys–Dietz syndrome; nephropathy; Diastolic HF; fibrotic lung complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermansky-Pudlak syndrome, liver disorders, such as non- alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine disease such as uterine fibroids and uterine or cervical fibrosis.

  本发明涉及一种化学式（1）中的D-半乳糖吡喃糖类化合物，其中吡喃糖环为α-D-半乳糖吡喃糖，这些化合物是高亲和力的galectin-3抑制剂，用于治疗炎症；炎症诱导性血栓形成；特应性皮炎；急性冠状动脉综合征；纤维化，如肺纤维化、肝脏纤维化、肾脏纤维化、眼科纤维化和皮肤和心脏的纤维化；局部纤维化，如杜普伊特伦氏病和佩罗尼氏病；其他治疗的纤维化并发症，如冠状支架、胆管支架、脑动脉支架、输尿管支架；硬皮病；瘢痕形成；瘢痕增生；新冠肺炎；急性肺损伤；ARDS；病毒性肺炎；异常瘢痕形成；手术粘连；脓毒性休克；癌症，如结直肠癌、其他胃肠道癌症如胰腺癌、胃癌、胆道癌、肺癌、间皮瘤、女性癌症如乳腺癌、卵巢癌、子宫癌、宫颈癌、输卵管癌、脑癌如髓母细胞瘤、胶质瘤、脑膜瘤、骨骼和肌肉的肉瘤和其他肉瘤、白血病和淋巴瘤，如T细胞淋巴瘤；移植排斥；转移性癌症；衰老；痴呆症；阿尔茨海默病；TGFbeta驱动的骨疾病，如骨发育不全；肺动脉高压；自身免疫疾病，如牛皮癣、类风湿关节炎、类风湿肺；克罗恩病、溃疡性结肠炎、强直性脊柱炎、系统性红斑狼疮；病毒感染，如流感病毒、HIV、疱疹病毒、冠状病毒、丙型肝炎；代谢紊乱；心脏病；心力衰竭；病理性血管生成，如眼部血管生成或与眼部血管生成相关的疾病或症状，例如与癌症相关的新血管生成；眼部疾病，如老年性黄斑变性和角膜新血管生成；动脉粥样硬化；代谢性疾病；糖尿病；1型糖尿病；2型糖尿病；胰岛素抵抗；肥胖；马凡氏综合征；洛伊斯-迪茨综合征；肾病；舒张期心力衰竭；PD1和其他CPI疗法的肺纤维化并发症；哮喘和其他间质性肺疾病，包括赫尔曼斯基-普德拉克综合征、肝脏疾病，如非酒精性脂肪性肝炎或非酒精性脂肪肝病；子宫疾病，如子宫肌瘤和子宫或宫颈纤维化。
• A general strategy for the formal synthesis of (−)-trans-kumausyne and total synthesis of (5R)-Hagen’s gland lactones from diacetone-d-glucose
  作者：Hari Babu Mereyala、Rajendrakumar Reddy Gadikota

  DOI：10.1016/s0957-4166(99)00575-3

  日期：2000.2

  A general strategy for the formal synthesis of (−)-trans-kumausyne 1 via the bicyclic lactone (3aR,5R,6aR)-4 and total synthesis of (5R)-Hagen’s gland lactones 2 and 3 via bicyclic lactone (3aR,5S,6aR)-5 starting from diacetone-d-glucose 6 is described. Syntheses of 4 and 5 were achieved by Wittig olefination–lactonization–Michael addition of the corresponding lactols 16 and 17, respectively.

  - （ - ）为正式合成的一般策略反-kumausyne 1经由二环内酯（3A - [R，5 - [R，6α - [R ） - 4和（5全合成- [R）-Hagen腺内酯2和3经由二环内酯描述了从双丙酮-d-葡萄糖6开始的（3a R，5 S，6a R）-5。4和5的合成是通过Wittig烯烃化-内酯化-迈克尔加成相应的内酯16和17来实现的， 分别。
• Studies on the Total Synthesis of Antibiotic Macrolactin S: A Conventional Approach for the Synthesis of the C1–C9 and C10–C24 Fragments
  作者：Pabbaraja Srihari、Ramakrishna Sayini

  DOI：10.1055/s-0036-1589132

  日期：2018.2

  adopted for the synthesis of the key C10–C24 fragment. The C1–C9 and C10–C24 segments of the 24-membered polyene macrolide macrolactin S were synthesized by routes involving an epoxide-ring-opening reaction, an Ohira–Bestmann alkyne formation, a chelation-controlled nucleophilic addition reaction, and a Still–Gennari olefination as key steps. A chiron approach , starting from readily available glucose diacetonide

  摘要 通过以下方法合成了24元多烯大环内酯大环内酯S的C1-C9和C10-C24节段：环氧化物-开环反应，Ohira-Bestmann炔烃形成，螯合控制的亲核加成反应以及Still- Gennari烯烃化是关键步骤。从容易获得的葡萄糖二丙酮化物开始，采用卡隆方法合成关键中间体，并采用收敛方法合成关键C10–C24片段。 通过以下方法合成了24元多烯大环内酯大环内酯S的C1-C9和C10-C24节段：环氧化物-开环反应，Ohira-Bestmann炔烃形成，螯合控制的亲核加成反应以及Still- Gennari烯烃化是关键步骤。从容易获得的葡萄糖二丙酮化物开始，采用卡隆方法合成关键中间体，并采用收敛方法合成关键C10–C24片段。
• Synthesis of optically active O-protected (S)- and (R)-3-hydroxyaldehydes
  作者：Suk-Ku Kang、Hyun-Sung Cho

  DOI：10.1016/s0040-4039(00)92630-3

  日期：1991.1

  (S)-3-Formyloxyaldehydes, chiral synthons for natural product synthesis were synthesized via highly stereoselective hydrogenation of the unsaturated furanose ring system derived from D-glucose or D-xylose. Alternatively, (R)-3-formyloxyaldehydes were prepared via deoxygenation of 3-hydroxyfuranoses derived from D-glucose or D-xylose.

  通过高度立体选择性氢化衍生自D-葡萄糖或D-木糖的不饱和呋喃糖环系统合成了用于天然产物合成的（S）-3-Formyloxyaldehydes，手性合成子。或者，通过使衍生自D-葡萄糖或D-木糖的3-羟基呋喃糖酶脱氧制备（R）-3-甲酰氧基醛。
• Formal synthesis of fostriecin by a carbohydrate-based approach
  作者：J.S. Yadav、I. Prathap、Bulli Padmaja Tadi

  DOI：10.1016/j.tetlet.2006.03.116

  日期：2006.5

  The formal synthesis of fostriecin starting from d-glucose, involves chelation-controlled addition, Wittig rearrangement, ring closing metathesis and iodomethylenation, as described.

  如前所述，从d-葡萄糖开始的正式合成ostostriecin涉及螯合控制的加成，Wittig重排，闭环易位和碘甲基化。